|
業務類別
|
Biotechnology |
|
業務概覽
|
ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States. |
| 公司地址
| 3530 John Hopkins Court, San Diego, CA, USA, 92121 |
| 電話號碼
| +1 844 696-5235 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.immunitybio.com |
| 員工數量
| 691 |
| Dr. Patrick Soon-Shiong, F.A.C.S.,M.D. |
Executive Chairman of the Board, Global Chief Scientific and Medical Officer |
美元 648.83K |
30/04/2026 |
| Ms. Regan J. Lauer |
Chief Accounting Officer |
美元 338.77K |
30/04/2026 |
| Dr. Barry J. Simon, M.D. |
Chief Corporate Affairs Officer and Director |
-- |
30/04/2026 |
| Mr. Richard Adcock |
Chief Executive Officer, President and Director |
美元 831.67K |
30/04/2026 |
| Mr. David C. Sachs |
Chief Financial Officer |
美元 591.71K |
30/04/2026 |
|
|
| Mr. Michael D. Blaszyk |
Independent Director |
30/04/2026 |
| General Sir Wesley Kanne Clark |
Independent Director |
30/04/2026 |
| Dr. Patrick Soon-Shiong, F.A.C.S.,M.D. |
Executive Chairman of the Board, Global Chief Scientific and Medical Officer |
30/04/2026 |
| Ms. Cheryl L. Cohen |
Lead Independent Director |
30/04/2026 |
| Mr. Bruce J. Wendel |
Independent Director |
30/04/2026 |
| Dr. Barry J. Simon, M.D. |
Chief Corporate Affairs Officer and Director |
30/04/2026 |
| Dr. Linda Maxwell, M.B.A.,M.D. |
Independent Director |
30/04/2026 |
| Mr. Richard Adcock |
Chief Executive Officer, President and Director |
30/04/2026 |
| Ms. Christobel Selecky |
Independent Director |
30/04/2026 |
|
|
|
|
